Learn about atypical hemolytic uremic syndrome (aHUS)
atypical hemolytic uremic syndrome (aHUS) is a life threatening disease with devastating consequences
It may be scary to find out that you or your loved one may have aHUS. Although aHUS is a life-threatening disease, learning about your disease is important. The more you know, the better you can manage it.1
Here are some key facts about aHUS:
- aHUS is caused by genetic problems in the complement system, which is a part of the body's immune system
- aHUS is important to diagnose accurately because it has signs and symptoms that are similar to those of other diseases.2 Differentiating aHUS from other similar diseases as soon as possible is very important3,4
- Plasma exchange/infusion has been used to manage aHUS symptoms, but plasma therapy has not been studied in well-controlled trials1
Learn more about aHUS
- What Is aHUS?
aHUS is a disease of uncontrolled complement activation that affects as many adults as it does children.5,6
- How Do You Get aHUS?
aHUS is caused by a change, or mutation, in a person's genes. However, the absence of an identified genetic mutation does not rule out aHUS.8
- How is aHUS Diagnosed?
It's important to diagnose aHUS accurately because it has signs and symptoms similar to those of other diseases.2
- What Are the Risks of aHUS?
People with aHUS have an ongoing risk of sudden, life-threatening complications.1
- What Are the Treatments for aHUS?
Historical management options for aHUS have not been demonstrated in prospective clinical trials to be either safe or effective.7
- Discuss aHUS with Your Doctor
Here you will find guides to help you and your doctor work together on managing aHUS, whether you're new to the disease or currently being treated for aHUS.
1. Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10(suppl 17):1-12. 2. Legendre CM, Licht C, Muus P, et al. N Engl J Med. 2013;368:2169-2181. 3. Sellier-Leclerc A-L, Frémeaux-Bacchi V, Dragon-Durey MA, et al; French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-2400. 4. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8:622-633. 5. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. 6. Caprioli J, Noris M, Brioschi S, et al; for the International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279. 7. Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2013; DOI: 10.1002/jca.21302. [Epub ahead of print]. 8. Cofiell R, Kukreja A, Bedard K, et al. Poster presented at the 55th Annual Meeting of the American Society of Hematology; December 7-10, 2013; New Orleans, LA. Abstract 2184.